Blood

Groundbreaking New Blood Test Offers Early Pancreatic Cancer Diagnosis Study Says

Retrieved on: 
Thursday, February 29, 2024

LONG BEACH, Calif., Feb. 29, 2024 /PRNewswire/ -- As reported in today's issue of the journal Metabolites, researchers at Metabolomycs, a California-based biotechnology company, for the first time applied targeted mass spectrometry to show that pancreatic cancer arises through changes in cellular metabolism and that these changes can be measured with a simple blood test.

Key Points: 
  • "Pancreatic cancer is the third leading cause of death from cancer largely because it is rarely caught early," said Dr. Robert Nagourney, senior author.
  • Using Mass Spectrometry to measure minute concentrations of bio-chemicals in the plasma, the technique identified pancreatic cancer in the blood with near perfect accuracy.
  • The results provide a "cancer signature" that distinguishes patients with pancreatic cancer from normal individuals and can distinguish pancreatic cancer from other forms of cancer, like breast and ovarian.
  • Following Genomics, the study of DNA and Proteomics, the study of cell proteins, metabolomics, is the new "omic" to watch.

How Cinesteam® Helps Manage Smells From Diabetic Foot

Retrieved on: 
Thursday, February 29, 2024

FORT LAUDERDALE, Fla., Feb. 29, 2024 /PRNewswire/ -- Diabetic foot is a common concern for those with diabetes. The condition can lead to chronic wounds that produce highly unpleasant smells. Cinesteam® is a natural-based secondary dressing designed to simply and effectively manage smells like those that come from diabetic foot.

Key Points: 
  • FORT LAUDERDALE, Fla., Feb. 29, 2024 /PRNewswire/ -- Diabetic foot is a common concern for those with diabetes.
  • Cinesteam® is a natural-based secondary dressing designed to simply and effectively manage smells like those that come from diabetic foot.
  • The medical condition comes with many health concerns, one of which is commonly referred to as "diabetic foot."
  • Mayo Clinic reports that as much as 50% of those with diabetes can be affected by diabetic neuropathy, opening the doors for diabetic foot to develop.

BioInnovation Institute welcomes twelve new companies to its Venture Lab program

Retrieved on: 
Thursday, February 29, 2024

COPENHAGEN, Denmark, Feb. 29, 2024 /PRNewswire/ -- BioInnovation Institute (BII), an international non-profit foundation incubating and accelerating world-class life science research, today announces that twelve new companies have entered its Venture Lab acceleration program for early-stage companies.

Key Points: 
  • COPENHAGEN, Denmark, Feb. 29, 2024 /PRNewswire/ -- BioInnovation Institute (BII), an international non-profit foundation incubating and accelerating world-class life science research, today announces that twelve new companies have entered its Venture Lab acceleration program for early-stage companies.
  • In becoming a part of the Venture Lab program, the early-stage companies also get an exclusive opportunity to apply for EUR 1.3M in follow-up funding through BII's Venture House program.
  • We once again look forward to supporting these start-ups in bringing their innovations into fruition by providing our knowledge, network, funding, and infrastructure to build successful companies."
  • The new companies BII has accepted into the Venture Lab acceleration program are:
    CAMBIOTICS is developing precision probiotics for PFAS detoxification.

BioInnovation Institute welcomes twelve new companies to its Venture Lab program

Retrieved on: 
Thursday, February 29, 2024

COPENHAGEN, Denmark, Feb. 29, 2024 /PRNewswire/ -- BioInnovation Institute (BII), an international non-profit foundation incubating and accelerating world-class life science research, today announces that twelve new companies have entered its Venture Lab acceleration program for early-stage companies.

Key Points: 
  • COPENHAGEN, Denmark, Feb. 29, 2024 /PRNewswire/ -- BioInnovation Institute (BII), an international non-profit foundation incubating and accelerating world-class life science research, today announces that twelve new companies have entered its Venture Lab acceleration program for early-stage companies.
  • In becoming a part of the Venture Lab program, the early-stage companies also get an exclusive opportunity to apply for EUR 1.3M in follow-up funding through BII's Venture House program.
  • We once again look forward to supporting these start-ups in bringing their innovations into fruition by providing our knowledge, network, funding, and infrastructure to build successful companies."
  • The new companies BII has accepted into the Venture Lab acceleration program are:
    CAMBIOTICS is developing precision probiotics for PFAS detoxification.

Hanvon Technology Launches Groundbreaking Fourth-Generation BP Meter Based on Korotkoff Sound Method

Retrieved on: 
Thursday, February 29, 2024

BEIJING, Feb. 28, 2024 /PRNewswire/ -- Hanvon Technology Co., Ltd., based in China, has launched the world's first smart electronic BP Meter utilizing the Korotkoff sound method. This device integrates advanced sensor technology with artificial intelligence algorithms, overcomes the accuracy limitations of traditional electronic BP Meter, and achieves the precision of mercury sphygmomanometers; it starts a new era of Electronic BP Meters.

Key Points: 
  • BEIJING, Feb. 28, 2024 /PRNewswire/ -- Hanvon Technology Co., Ltd., based in China, has launched the world's first smart electronic BP Meter utilizing the Korotkoff sound method.
  • This device integrates advanced sensor technology with artificial intelligence algorithms, overcomes the accuracy limitations of traditional electronic BP Meter, and achieves the precision of mercury sphygmomanometers; it starts a new era of Electronic BP Meters.
  • The Korotkoff sound method, developed by Russian physician Nikolai Korotkoff in 1905.
  • Hanvon BP Meter with Korotkoff sound method is now available in China mainland, and is expected to enter the international market in the near future.

Reese Pharmaceutical Launches New At-Home Colon Cancer Screening Test

Retrieved on: 
Tuesday, February 27, 2024

CLEVELAND, Feb. 27, 2024 /PRNewswire/ -- Reese Pharmaceutical is expanding its over-the-counter (OTC) diagnostic portfolio with the launch of ColoTest®, an at-home Fecal Immunochemical Test (FIT) that identifies the presence of hidden blood in the stool in support of the early detection of colon cancer or gastrointestinal disorders such as colitis, diverticulitis, and polyps.

Key Points: 
  • A recent report by the American Cancer Society revealed a troubling spike in new colon and rectal cancer diagnoses across the US.
  • "90% of colon cancer-related deaths are thought to be preventable if caught early, and yet more than 29 million Americans are not screening for it.
  • With colon cancer rates on the rise, it is more important than ever for people to be proactive.
  • This test is performed in the comfort of your own home with results at home as soon as 1 minute," said Jeffrey Reese, President, of Reese Pharmaceutical.

Inspira™ Announces Breakthrough Update: Nears First FDA 510(k) Approval, 3 U.S. Patents Approved, $546 million in Summary Distribution Agreements

Retrieved on: 
Tuesday, February 27, 2024

Three breakthrough patents have been approved by the United States Patent and Trademark Office ("USPTO") and an additional three patent applications are pending at the USPTO for certain core technologies.

Key Points: 
  • Three breakthrough patents have been approved by the United States Patent and Trademark Office ("USPTO") and an additional three patent applications are pending at the USPTO for certain core technologies.
  • To date, the Company has signed $546 million in pre-conditioned summary distribution agreements, subject to regulatory approvals and authorizing authorities.
  • We vision the INSPIRA ART is expected to changing the medical landscape, with the VORTX orbiting blood oxygenation delivery system.
  • The Company has developed a breakthrough Augmented Respiration Technology (INSPIRA ART), designed to rebalance patient oxygen saturation levels.

Innocan Pharma Announces Study Findings that LPT-CBD maintains its prolonged release in Rabbits

Retrieved on: 
Monday, February 26, 2024

The fundamentals of LPT-CBD lay in its ability to slowly release CBD into the blood stream.

Key Points: 
  • The fundamentals of LPT-CBD lay in its ability to slowly release CBD into the blood stream.
  • In the Company's latest study conducted on rabbits, the results showed additional supportive data for the long exposure of CBD obtained following a single subcutaneous LPT-CBD injection.
  • The Company is encouraged by these study results as they confirm the approach the Company is taking with its LPT platform.
  • In the study conducted on rabbits, the animals were collected for blood analysis of the drug for up to 11 days.

Suburban Propane Commemorates Black History Month with Reception Celebrating Dr. Charles R. Drew and Hosts Sickle Cell Blood Drive with the American Red Cross

Retrieved on: 
Monday, February 26, 2024

Dr. Drew is remembered for his research in blood transfusions and for developing improved techniques for blood storage.

Key Points: 
  • Dr. Drew is remembered for his research in blood transfusions and for developing improved techniques for blood storage.
  • The drive was part of an ongoing effort by the American Red Cross to increase blood donations in support of individuals battling sickle cell disease.
  • Blood transfusion is an essential treatment for sickle cell disease—the most common genetic blood disease in the United States, primarily affecting Black individuals.
  • "Blood transfusion is an essential aspect of treatment for sickle cell disease, which primarily affects Black and African American individuals," said Rosie Taravella, CEO, the American Red Cross New Jersey Region.

Hoth Therapeutics Engages Altasciences to Perform Key Study for HT-KIT Cancer Fighting Therapeutic

Retrieved on: 
Monday, February 26, 2024

NEW YORK, Feb. 26, 2024 /PRNewswire/ -- Hoth Therapeutics, Inc. (NASDAQ: HOTH), a patient-focused biopharmaceutical company, announced today that it has completed bioanalytical method development under its prior agreement with Altasciences and plans to further engage Altasciences to perform a key study of mouse blood and plasma analysis from samples collected in Hoth's sponsored scientific research conducted at NC State University.  The blood and plasma samples collected are part of a dose response study in a humanized mouse model. The upcoming study will use the newly validated bioanalytical method developed at Altasciences to test the amount of HT-KIT from the dose response study and help determine how long HT-KIT remains in the blood stream post dosing.

Key Points: 
  • NEW YORK, Feb. 26, 2024 /PRNewswire/ -- Hoth Therapeutics, Inc. (NASDAQ: HOTH), a patient-focused biopharmaceutical company, announced today that it has completed bioanalytical method development under its prior agreement with Altasciences and plans to further engage Altasciences to perform a key study of mouse blood and plasma analysis from samples collected in Hoth's sponsored scientific research conducted at NC State University.
  • The blood and plasma samples collected are part of a dose response study in a humanized mouse model.
  • The upcoming study will use the newly validated bioanalytical method developed at Altasciences to test the amount of HT-KIT from the dose response study and help determine how long HT-KIT remains in the blood stream post dosing.
  • "We are pleased to further engage Altasciences on these studies given its great reputation for full-service solutions including preclinical safety testing, clinical pharmacology and bioanalysis."